Retinal pigment epithelial marginal retraction after photodynamic therapy for choroidal neovascularization in pathologic myopia.
OBJECTIVE
To report the incidence of retinal pigment epithelial (RPE) marginal retraction after verteporfin photodynamic therapy (PDT) for subfoveal choroidal neovascularization (CNV) in pathologic myopia (PM).


METHODS
Retrospective review of 236 patients treated with PDT for subfoveal CNV due to PM.


RESULTS
RPE marginal retraction was found in 3 eyes (1.3%), and a decrease of a mean of five lines of vision was reported to occur 10-15 days after treatment. At the end of followup two eyes lost three lines and one six lines from baseline.


CONCLUSIONS
RPE marginal retraction as an early complication of PDT for subfoveal CNV secondary to PM is rare. The low incidence of this adverse event, however, should not preclude recommendations for PDT in myopic eyes that could benefit from this treatment modality.
Pece
A
A
Department of Ophthalmology, Melegnano Hospital, Milano - Italy. pece.retina@mclink.it
Isola
V
V
D000328:Adult; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D010778:Photochemotherapy / Q000009:adverse effects*; D017319:Photosensitizing Agents / Q000009:adverse effects; D010857:Pigment Epithelium of Eye / Q000187:drug effects*; D011166:Porphyrins / Q000009:adverse effects; D012164:Retinal Diseases / Q000139:chemically induced*; D000077362:Verteporfin; D014792:Visual Acuity
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin